📊 IRMD Key Takeaways
Is Iradimed Corp. (IRMD) a Good Investment?
IRMD demonstrates exceptional profitability and operational efficiency with 76.5% gross margins, 32.9% operating margins, and strong free cash flow generation (35.9% FCF margin), backed by a fortress balance sheet with no debt and 56.4M in cash. However, completely flat revenue growth (0% YoY) combined with weak ROE of 5.9% indicates the business is mature and not effectively deploying its substantial cash reserves, creating uncertainty about future value creation.
IRADIMED shows unusually strong fundamentals, with very high gross, operating, and net margins alongside solid free cash flow generation and a debt-free balance sheet. Financial health is excellent given its large cash position, high liquidity, and strong returns on equity and assets. The main limitation is growth quality right now, as revenue and net income appear flat, so continued upside depends on reaccelerating top-line expansion without sacrificing margins.
Why Buy Iradimed Corp. Stock? IRMD Key Strengths
- Exceptional profitability: 76.5% gross margin, 32.9% operating margin, 26.5% net margin in medical device sector
- Fortress balance sheet: Zero long-term debt, 49.3% of assets in cash, 7.13x current ratio provides significant financial flexibility and downside protection
- Strong cash generation: Operating cash flow of 8.3M with 35.9% FCF margin despite flat revenue, indicating highly efficient capital-light business model
- Improving operational efficiency: 16.7% EPS growth YoY despite flat revenue demonstrates cost control and shareholder-focused management
- Exceptional profitability, including 76.7% gross margin and 31.2% operating margin
- Very strong balance sheet with $51.16M in cash, no long-term debt, and low liabilities
- Healthy cash generation, with $24.95M operating cash flow and $17.18M free cash flow
IRMD Stock Risks: Iradimed Corp. Investment Risks
- Zero revenue growth signals market saturation, competitive pressure, or structural headwind in medical device segment requiring investigation
- Low returns on assets (ROE 5.9%, ROA 5.1%) with 56.4M cash position suggests capital is not being deployed productively or strategically
- Accumulated cash without clear deployment strategy may indicate uncertainty about growth opportunities or acquisition targets in competitive market
- Asset-light business (403K CapEx) on flat revenue may indicate insufficient R&D investment or lack of innovation pipeline for future growth
- Revenue growth appears stalled, which raises questions about near-term expansion potential
- Net income was flat year over year, suggesting current earnings growth is not being driven by business growth
- High profitability may be difficult to sustain if costs rise or sales mix weakens
Key Metrics to Watch
- Revenue growth trajectory and quarterly trends - must confirm if flat growth is temporary or structural decline
- Management's capital allocation strategy - watch for M&A, share buybacks, dividends, or reinvestment announcements signaling cash deployment plans
- Operating cash flow sustainability and conversion rates as business matures
- R&D spending levels and new product pipeline health in competitive surgical instruments market
- Revenue growth and order momentum
- Free cash flow conversion and operating margin stability
Iradimed Corp. (IRMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 35.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 7.13x current ratio provides a solid financial cushion.
IRMD Profit Margin, ROE & Profitability Analysis
IRMD vs Healthcare Sector: How Iradimed Corp. Compares
How Iradimed Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Iradimed Corp. Stock Overvalued? IRMD Valuation Analysis 2026
Based on fundamental analysis, Iradimed Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Iradimed Corp. Balance Sheet: IRMD Debt, Cash & Liquidity
IRMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Iradimed Corp.'s revenue has grown significantly by 100% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.50 reflects profitable operations.
IRMD Revenue Growth, EPS Growth & YoY Performance
IRMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $19.5M | $4.7M | $0.37 |
| Q3 2025 | $18.3M | $4.1M | $0.40 |
| Q2 2025 | $17.9M | $4.1M | $0.38 |
| Q1 2025 | $17.6M | $4.1M | $0.32 |
| Q3 2024 | $16.5M | $3.4M | $0.40 |
| Q2 2024 | $16.1M | $3.4M | $0.33 |
| Q1 2024 | $15.5M | $3.4M | $0.27 |
| Q3 2023 | $13.4M | $2.5M | $0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Iradimed Corp. Dividends, Buybacks & Capital Allocation
IRMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Iradimed Corp. (CIK: 0001325618)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRMD
What is the AI rating for IRMD?
Iradimed Corp. (IRMD) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRMD's key strengths?
Claude: Exceptional profitability: 76.5% gross margin, 32.9% operating margin, 26.5% net margin in medical device sector. Fortress balance sheet: Zero long-term debt, 49.3% of assets in cash, 7.13x current ratio provides significant financial flexibility and downside protection. ChatGPT: Exceptional profitability, including 76.7% gross margin and 31.2% operating margin. Very strong balance sheet with $51.16M in cash, no long-term debt, and low liabilities.
What are the risks of investing in IRMD?
Claude: Zero revenue growth signals market saturation, competitive pressure, or structural headwind in medical device segment requiring investigation. Low returns on assets (ROE 5.9%, ROA 5.1%) with 56.4M cash position suggests capital is not being deployed productively or strategically. ChatGPT: Revenue growth appears stalled, which raises questions about near-term expansion potential. Net income was flat year over year, suggesting current earnings growth is not being driven by business growth.
What is IRMD's revenue and growth?
Iradimed Corp. reported revenue of $22.0M.
Does IRMD pay dividends?
Iradimed Corp. pays dividends, with $2.6M distributed to shareholders in the trailing twelve months.
Where can I find IRMD SEC filings?
Official SEC filings for Iradimed Corp. (CIK: 0001325618) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRMD's EPS?
Iradimed Corp. has a diluted EPS of $0.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRMD a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Iradimed Corp. has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is IRMD stock overvalued or undervalued?
Valuation metrics for IRMD: ROE of 5.9% (sector avg: 15%), net margin of 26.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRMD stock in 2026?
Our dual AI analysis gives Iradimed Corp. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is IRMD's free cash flow?
Iradimed Corp.'s operating cash flow is $8.3M, with capital expenditures of $403.0K. FCF margin is 35.9%.
How does IRMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 26.5% (avg: 12%), ROE 5.9% (avg: 15%), current ratio 7.13 (avg: 2).